Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.
about
Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate modelAdeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectorsEmerging Vaccine TechnologiesStructure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectorsDesigner gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transferIntraocular route of AAV2 vector administration defines humoral immune response and therapeutic potentialAAV's anatomy: roadmap for optimizing vectors for translational successComparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9.Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposureAdeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblastsNaturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo.Current status of gene therapy for cystic fibrosis pulmonary disease.Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Directed evolution of novel adeno-associated viruses for therapeutic gene delivery.Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain.Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brainGene therapy using adeno-associated virus vectorsPrevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brainImmunological hurdles to lung gene therapy.Immune responses to adeno-associated virus and its recombinant vectors.Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering.Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advancesImmune responses to gene therapy vectors: influence on vector function and effector mechanisms.Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).Augmentation of transgene-encoded protein after neonatal injection of adeno-associated virus improves hepatic copy number without immune responses.Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.Gene Therapy for Duchenne muscular dystrophy.Lack of repeat transduction by recombinant adeno-associated virus type 5/5 vectors in the mouse airwayPrediction of adeno-associated virus neutralizing antibody activity for clinical application.Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector.Regulatory function of in vivo anergized CD4(+) T cellsAAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesThe complex and evolving story of T cell activation to AAV vector-encoded transgene products.
P2860
Q24527302-D4B81C7F-4C2D-414E-9531-B0B7A273A80FQ24529153-56A163DB-060B-4536-878F-3771C22A62E5Q26783764-0588C11B-F9E1-4093-A023-795A7B97009DQ27681034-610F20C2-D843-4C5C-9419-25C7C1C219E2Q28730577-BE335666-74BD-440C-9BFC-841255CC8F55Q33296224-E2F9346A-004D-426F-BD96-ADD3F3AF5A5DQ33374015-F3BB573C-08DF-406C-B4BF-572A5C67A50AQ33659389-26143272-3740-4041-9AA4-B95694B28BDEQ33713259-385EDD1B-9253-4CFA-A52A-7D6E8D03CC67Q33713348-E0CF6667-082F-46AF-83EC-48F38B6C94CEQ33786029-B14C14F4-98C8-4435-99FE-205925EC7720Q33839187-ADAA4F5D-E01F-4086-83FB-F658B4E295D2Q33924645-181C7AD1-9281-49EB-88DE-A177B4E39023Q33975113-5FBACA98-4C6A-45D5-9B2D-C330056459A1Q34069571-C6BAAC36-4B58-47E7-8145-D1962671C5A1Q34188892-CC2CFEE3-2346-469C-9064-5C5E8594703EQ34193457-4CABDBF5-D43A-430C-B2CD-0A1E75B679D8Q34434903-1BF22F02-F3FF-4F44-A54B-8871F5067B30Q34566454-EE22F818-6F67-40D1-8FDB-0C5D58F5DBA8Q34718452-39041BE4-3FE4-439A-999A-001B01021961Q34852719-F43AE72A-C8EC-4594-8AD4-9CE02E88FB95Q34938807-8224A586-2EA1-476F-89B2-D60807E67B6FQ35000819-5B81A266-72FA-43C0-A8EA-FB26BBBC9A98Q35091006-04EA0078-29B4-4838-A906-5BF370C81740Q35131229-E670337F-1288-4A56-962D-50A5D0F2CD52Q35450610-E388CE07-ECBD-4AF7-9272-D1AA5B569BD3Q35451204-4242A6D0-20CD-420F-818F-6F5B5DF1647EQ35847178-02C80229-14DE-424F-837C-F6F40B9B056FQ35904408-56E3048D-6B60-4D3D-83FE-ECF8208D0A67Q35904461-DDC811F1-90BA-4518-871D-83DA6AB145BFQ35967470-7A78E43F-CFC2-4C86-A988-399666F728DDQ36171820-8529A7A6-B619-4587-976C-4EFFC329EFAFQ36295934-47E04B66-16D0-4043-BBCD-E6D2FA1DC4DFQ36315561-B35D4402-AA03-4964-87A1-8BFAE18F258CQ36348346-89D75C93-D169-4070-A447-4E1A50E2AFD2Q36582796-5AD8145E-DD5E-43D9-806B-64A4C9DF5164Q37113443-F320C2F9-6F1B-4F52-BBF5-240E5C7327C0Q37571781-2BF22AA0-64B0-4355-915C-59F69D3CC617Q37621530-5E2731A4-4ADA-47AD-9FF3-D4FF7FD7C5BBQ37814051-66750543-412C-4957-807A-65050055D183
P2860
Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Transient immunosuppression al ...... deno-associated viral vectors.
@en
Transient immunosuppression al ...... deno-associated viral vectors.
@nl
type
label
Transient immunosuppression al ...... deno-associated viral vectors.
@en
Transient immunosuppression al ...... deno-associated viral vectors.
@nl
prefLabel
Transient immunosuppression al ...... deno-associated viral vectors.
@en
Transient immunosuppression al ...... deno-associated viral vectors.
@nl
P2093
P356
P1433
P1476
Transient immunosuppression al ...... deno-associated viral vectors.
@en
P2093
P304
P356
10.1089/HUM.1998.9.4-477
P577
1998-03-01T00:00:00Z